Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kassimos, D. G.
Right arrow Articles by Kitas, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassimos, D. G.
Right arrow Articles by Kitas, G. D.
Related Collections
Right arrow Osteoarthritis and Cartilage
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 490
© 2003 British Society for Rheumatology

Letters to the Editor

Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines

D. G. Kassimos, A. Garyfallos1, J. Delamere, A. Whallett and G. D. Kitas

Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, DY1 4S, UK and
1 4th Department of Internal Medicine, Hippocratio Hospital, Medical School University of Thessaloniki, Greece

The first 10% of the full text of this article appears below.

SIR, Several investigators have recently reported significant clinical and serological improvement in patients with ankylosing spondylitis (AS) treated with the anti-tumour necrosis factor (TNF) agents infliximab [. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?